Last reviewed · How we verify
Ruxolitinib Topical Cream 1.5%
Ruxolitinib Topical Cream 1.5% is a Small molecule drug developed by Sun Pharmaceutical Industries, Inc.. It is currently in Phase 1 development. Also known as: Test Product.
At a glance
| Generic name | Ruxolitinib Topical Cream 1.5% |
|---|---|
| Also known as | Test Product |
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Application site pain
- COVID-19
- Urinary tract infection
- Application site acne
- Application site pruritus
- Dermatitis contact
- Pruritus
- Vulvovaginal mycotic infection
- Abdominal pain
Key clinical trials
- Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease (PHASE2)
- A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis (PHASE3)
- Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis (PHASE2)
- Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) (PHASE3)
- Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) (PHASE3)
- Topical Ruxolitinib Evaluation in Chronic Hand Eczema (PHASE2)
- Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis (PHASE3)
- Ruxolitinib in Seborrheic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ruxolitinib Topical Cream 1.5% CI brief — competitive landscape report
- Ruxolitinib Topical Cream 1.5% updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI
Frequently asked questions about Ruxolitinib Topical Cream 1.5%
What is Ruxolitinib Topical Cream 1.5%?
Ruxolitinib Topical Cream 1.5% is a Small molecule drug developed by Sun Pharmaceutical Industries, Inc..
Who makes Ruxolitinib Topical Cream 1.5%?
Ruxolitinib Topical Cream 1.5% is developed by Sun Pharmaceutical Industries, Inc. (see full Sun Pharmaceutical Industries, Inc. pipeline at /company/sun-pharmaceutical-industries-inc).
Is Ruxolitinib Topical Cream 1.5% also known as anything else?
Ruxolitinib Topical Cream 1.5% is also known as Test Product.
What development phase is Ruxolitinib Topical Cream 1.5% in?
Ruxolitinib Topical Cream 1.5% is in Phase 1.
What are the side effects of Ruxolitinib Topical Cream 1.5%?
Common side effects of Ruxolitinib Topical Cream 1.5% include Nasopharyngitis, Upper respiratory tract infection, Headache, Application site pain, COVID-19, Urinary tract infection.
Related
- Manufacturer: Sun Pharmaceutical Industries, Inc. — full pipeline
- Also known as: Test Product
- Compare: Ruxolitinib Topical Cream 1.5% vs similar drugs
- Pricing: Ruxolitinib Topical Cream 1.5% cost, discount & access